MAIA · MAIA Biotechnology, Inc.

📣 What MAIA Says Is Next

• next year · ateganosine: ““Interim data from the Phase 3 trial, expected next year, may support a discussion with the FDA to present our case for early full commercial approval in third-line NSCLC.” MAIA’s pivotal Phase 3 trial, THIO-104, evaluates the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) in third-line NSCLC patients who are resistant to checkpoint inhibitors alone and chemotherapy.”
  Company press release, Apr 8, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Jul 2027 · Phase 3 · Recruiting · A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced
  Registry primary completion date, not a results date
• Sep 2027 · Phase 2 · Active Trial · THIO Sequenced With Cemiplimab in Advanced NSCLC
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not MAIA's own candidates): Cemiplimab, Docetaxel Anhydrous, Vinorelbine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MAIA holds $27.6M in cash and short-term investments and burns about $5.6M/quarter from operations, an estimated runway of 14.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

• Cash runway 15 months +18
• Shelf registration (S-3, Aug 2026) +10
• Company says its financing fully funds the pivotal trial -10On April 8, 2026, we announced that net proceeds from the $33 million confidentially marketed public offering of common stock in March 2026 are expected to fully fund the Company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer (NSC 10-Q, Aug 2026
• Share count +84% in a year +20

Recent financing filings on SEC EDGAR:

• Aug 21, 2026 · Shelf registration · S-3
• May 14, 2026 · ATM program terminated · 424B5
• Mar 4, 2026 · Underwritten offering, $30M · 424B5
• Mar 2, 2026 · Underwritten offering · 424B5
• Dec 17, 2025 · Private placement (8-K Item 3.02) · 8-K
• Oct 14, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MAIA files for a raise →

👥 Who Owns MAIA

Share count 60,825,844 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.